Tokyo (JCNN) - Takeda Pharmaceutical (TSE: 4502) and Toray Industries (TSE: 3402) announced today that the companies have concluded a joint development and marketing agreement on an investigational compound for frequent urination/urinary incontinence.

Under the terms of the agreement, Takeda and Toray will jointly develop the compound, while Toray will market in Japan and Takeda will market overseas. The partners hope this collaboration will enable the efficient development processes and the earliest possible commercialization of this compound.

The compound is now in the preparation stage for Phase I studies in the U.S.

The compound, with development codes of TRK-130 for Toray and TAK-363 for Takeda, was found in Toray's compound library as a potential treatment for such diseases, through joint research by both parties started in June 2000.

Frequent urination and urinary incontinence are mostly seen as the symptoms of the overactive bladder (OAB) with increased patients in line with aging, and affect the quality of life (QOL) remarkably because the daily lifestyle habits such as the nighttime sleep or transportation are disturbed.

Presently, symptoms are treated with anticholinergic agents which are known to have side effects such as dry mouth, constant urge to urinate and constipation. Based on the findings to date, this compound has different mechanism of action to suppress the bladder hypersensitivity with high selectivity, and is expected to have lesser side effects which can be seen with the treatment by anticholinergic agents.

Therefore, the new compound can be a treatment option with a new action mechanism for frequent urination and urinary incontinence, contributing to improvement of the QOL of the patients.

View Takeda Pharmaceutical Company, Ltd. company profile here

Copyright 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.

Tag Cloud